

FIGURE 1







FIGURE 2




BEST AVAILABLE COPY




h4g human eIF4G B β KKRYDREFLLGFAARQIKIW FQNRRMKWKK
S scrambled eIF4G B β FDLKFALGRYRAEKRQIKIW FQNRRMKWKK
- no peptide
rec 4E recombinant human eIF4E

FIGURE 5



H	human eIF4G	B	β	β	K	K	R	<u>Y</u>	D	R	E	F	<u>L</u>	<u>L</u>	G	F	413-424
Y	yeast eIF4G	B	β	β	K	Y	T	<u>Y</u>	G	P	T	F	<u>L</u>	<u>L</u>	Q	F	449-460
W	wheat eIF4G	B	β	β	R	V	R	<u>Y</u>	S	R	D	Q	<u>L</u>	<u>L</u>	D	L	62-73
1	human 4E-BP1	B	β	β	R	I	I	<u>Y</u>	D	R	K	F	<u>L</u>	M	E	U	51-62
2	human 4E-BP2	B	β	β	R	I	I	<u>Y</u>	D	R	K	F	<u>L</u>	<u>L</u>	D	R	51-62
S	scrambled eIF4G																



FIGURE 6



4G Peptide	Sequence
H _{wt} hu 4G ₍₄₁₃₋₄₂₄₎	K K R <u>Y</u> D R E F <u>L</u> <u>L</u> G F A A
H _{3A} hu 4G ₍₄₁₃₋₄₂₄₎ YALALA	K K R A D R E F A A G F A A
W _{wt} wh 4G ₍₆₂₋₇₃₎	R V R <u>Y</u> S R D Q <u>L</u> <u>L</u> D L A A
W _{3A} wh 4G ₍₆₂₋₇₃₎ YALALA	R V R A S R D Q A A D L A A
S scrambled hu 4G	F D L K F A L G R Y R A E K

all peptides biotinylated and linked to Penetratin™

FIGURE 7



+ Positive control
 B human 4E-BP1
 W wheat eIF4G₍₆₂₋₇₃₎

FIGURE 8

Peptide	Concentration			
	3 μ M	6 μ M	9 μ M	12 μ M
hu 4G ₍₄₁₃₋₄₂₄₎	+	++	+++	+++
hu 4G ₍₄₁₃₋₄₂₄₎ Y416AL421AL422A	-	-	-	-
wh 4G ₍₆₂₋₇₃₎	-/+	+	++	+++
wh 4G ₍₆₂₋₇₃₎ Y65AL70AL71A	-	-	-	-
scrambled hu 4G	-	-	-	-

MRC5 cells, 72 h serum-free growth, all peptides biotinylated and linked to Penetratin™




FIGURE 9FIGURE 10

FIGURE 11



7/12

FIGURE 12

(a)

Hu 4G	Human eIF4G Peptide (569-580) Wild Type	KKRYDRE <u>F</u> LLGF
Hu 4G YLL-AAA	Human eIF4G Peptide (569-580) Y572A L577A L578A	KKRADRE <u>F</u> AAGF
Hu 4G Y-A	Human eIF4G Peptide (569-580) Y572A	KKRADRE <u>F</u> LLGF
Hu 4G L-A	Human eIF4G Peptide (569-580) L577A	KKRYDRE <u>F</u> ALGF
W4G	Wheat eIF4G Peptide (62-73) Wild Type	RVRYSRDQ <u>L</u> LDL
W4G YLL-AAA	Wheat eIF4G Peptide (62-73) Y65A, L70A, L71A	RVRASRDQ <u>A</u> ADL
BP2	Human 4E-BP2 Peptide (51-62) Wild Type	RIIYDRK <u>F</u> LLDR
BP2 YLL-AAA	Human 4E-BP2 Peptide (51-62) Y54A, L59A, L60A	RIIADRK <u>F</u> AADR
BP1	Human 4E-BP1 Peptide (51-62) Wild Type	RIIYDRK <u>F</u> LM <u>E</u> U
BP1 YLM-AAA	Human 4E-BP1 Peptide (51-62) Y54A, L59A, M60A	RIIADRK <u>F</u> AA <u>E</u> U

(b)






FIGURE 13


(a)



(b)



(c)



(d)






FIGURE 14



10/12


FIGURE 15



11/12

FIGURE 16


(a)




12/12

FIGURE 16 (cont.)

(b)



(c)



**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ **BLACK BORDERS**

☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☐ **FADED TEXT OR DRAWING**

☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☐ **SKEWED/SLANTED IMAGES**

☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**

☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.